%0 Journal Article
%T Drug-Induced Hypothyroidism during Anti-Tuberculosis Treatment of Multidrug-Resistant Tuberculosis: Notes from the Field
%A Somashekar Munivenkatappa
%A Singarajipura Anil
%A Balaji Naik
%A Tyson Volkmann
%A Karuna D. Sagili
%A Jayachamarajapura S. Akshatha
%A Shashidhar Buggi
%A Manchenahalli A. Sharada
%A Sudhendra Kulkarni
%A Vineet K. Chadha
%A Patrick K. Moonan
%J Journal of Tuberculosis Research
%P 105-110
%@ 2329-8448
%D 2016
%I Scientific Research Publishing
%R 10.4236/jtr.2016.43013
%X We followed 188 euthyroidic persons undergoing treatment for multidrug resistant tuberculosis (MDR-TB) in the state of Karnataka, India to determine the incidence of hypothyroidism during anti-tuberculosis treatment. Overall, among MDR-TB patients with valid thyroid stimulating hormone (TSH) values, about 23% developed hypothyroidism (TSH value ¡Ý10 mIU/ml) during anti-tuberculosis treatment; the majority (74%) occurring after 3 months of treatment. Among 133 patients who received a regimen that contained ethionamide, 42 (32%) developed hypothyroidism. Among 17 patients that received a regimen that contained para-aminosalicylate sodium, 6 (35%) developed hypothyroidism. Among 9 HIV positive patients on antiretroviral treatment, 4 (44%) developed hypothyroidism. These results differ from previously reported 4% incidence of hypothyroidism amongst patients who passively reported thyroidal symptoms during treatment, suggesting routine serologic monitoring of TSH throughout the course of treatment for MDR-TB is warranted.
%K Hypothyroidism
%K Multidrug Resistance
%K Tuberculosis
%K Thyroid-Stimulating
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=69978